财中社1月20日电科伦博泰生物-B(06990)发布公告,宣布公司已于2025年1月20日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB445新药临床试验申请的临床试验通知书。SKB445是一款由公司针对靶点生物学特征,利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物,临床前研究显示出良好的疗效和安全性,计划用于治疗晚期实体瘤。公告中提到,SKB445的最终成功...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.